Circulating anti-PLA2R autoantibodies to monitor immunological activity in membranous nephropathy

Journal of the American Society of Nephrology

Volumn 22, Issue 8, 2011, Pages 1400-1402

  Cravedi, Paolo ^a   Ruggenenti, Piero ^a   Remuzzi, Giuseppe ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD20 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NEUTROPHIL CYTOPLASMIC ANTIBODY; PHOSPHOLIPASE A2 RECEPTOR ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG; AUTOANTIBODY; MONOCLONAL ANTIBODY; PHOSPHOLIPASE A2 RECEPTOR;

B LYMPHOCYTE; EDITORIAL; FOCAL GLOMERULOSCLEROSIS; HUMAN; IDIOPATHIC MEMBRANOUS NEPHROPATHY; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROTEINURIA; ADULT; BLOOD; CHEMISTRY; COMPLEMENT ACTIVATION; IMMUNOLOGY; REMISSION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; AUTOANTIBODIES; COMPLEMENT ACTIVATION; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; RECEPTORS, PHOSPHOLIPASE A2; REMISSION INDUCTION;

EID: 79960932732     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2011060610     Document Type: Editorial

References (20)

1. Sacks S, Zhou W: New boundaries for complement in renal disease. J Am Soc Nephrol 19: 1865-1869, 2008
2. Gagliardini E, Conti S, Benigni A, Remuzzi G, Remuzzi A: Imaging of the porous ultrastructure of the glomerular epithelial filtration slit. J Am Soc Nephrol 21: 2081-2089, 2010
3. Ronco P, Debiec H: Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy. J Am Soc Nephrol 21: 564-569, 2010
4. Polanco N, Gutierrez E, Covarsi A, Ariza F, Carreno A, Vigil A, Baltar J, Fernandez-Fresnedo G, Martin C, Pons S, Lorenzo D, Bernis C, Arrizabalaga P, Fernandez-Juarez G, Barrio V, Sierra M, Castellanos I, Espinosa M, Rivera F, Oliet A, Fernandez-Vega F, Praga M: Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 21: 697-704, 2010
5. Ruggenenti P, Cravedi P, Remuzzi G: Latest treatment strategies for membranous nephropathy. Expert Opin Pharmacother 8: 3159-3171, 2007
6. Taylor RP, Lindorfer MA: Immunotherapeutic mechanisms of anti- CD20 monoclonal antibodies. Curr Opin Immunol 20: 444-449, 2008
7. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P: Rituximab for idiopathic membranous nephropathy. Lancet 360: 923-924, 2002 (Pubitemid 35283838)
8. Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C, Remuzzi G: Rituximab in idiopathic membranous nephropathy: A oneyear prospective study. J Am Soc Nephrol 14: 1851-1857, 2003 (Pubitemid 36750480)
9. Bomback AS, Derebail VK, McGregor JG, Kshirsagar AV, Falk RJ, Nachman PH: Rituximab therapy for membranous nephropathy: A systematic review. Clin J Am Soc Nephrol 4: 734-744, 2009
10. Fervenza FC, Cosio FG, Erickson SB, Specks U, Herzenberg AM, Dillon JJ, Leung N, Cohen IM, Wochos DN, Bergstralh E, Hladunewich M, Cattran DC: Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 73: 117-125, 2008 (Pubitemid 350273646)
11. Cravedi P, Sghirlanzoni MC, Marasa M, Salerno A, Remuzzi G, Ruggenenti P: Efficacy and safety of rituximab second-line therapy for membranous nephropathy: A prospective, matched-cohort study. Am J Nephrol 33: 461-468, 2011
12. Segarra A, Praga M, Ramos N, Polanco N, Cargol I, Gutierrez-Solis E, Gomez MR, Montoro B, Camps J: Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol 4: 1083-1088, 2009
13. Debiec H, Guigonis V, Mougenot B, Decobert F, Haymann JP, Bensman A, Deschenes G, Ronco PM: Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 346: 2053-2060, 2002 (Pubitemid 34680597)
14. Debiec H, Lefeu F, Kemper MJ, Niaudet P, Deschenes G, Remuzzi G, Ulinski T, Ronco P: Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med 364: 2101-2110, 2011
15. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ: M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361: 11-21, 2009
16. 2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 22: 1543-1550, 2011
17. Ruggenenti P, Chiurchiu C, Abbate M, Perna A, Cravedi P, Bontempelli M, Remuzzi G: Rituximab for idiopathic membranous nephropathy: who can benefit? Clin J Am Soc Nephrol 1: 738-748, 2006
18. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; RAVE-ITN Research Group: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363: 221-232, 2010
19. Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, Zilleruelo G, Abitbol C, Chandar J, Seeherunvong W, Ricordi C, Ikehata M, Rastaldi MP, Reiser J, Burke GW 3rd: Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 3: 85ra46, 2011
20. Bresin E, Gastoldi S, Daina E, Belotti D, Pogliani E, Perseghin P, Scalzulli PR, Paolini R, Marceno R, Remuzzi G, Galbusera M: Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thromb Haemost 101: 233-238, 2009